High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
This open-label, randomised, phase 2 trial was done at 22 public hospitals in Norway, Denmark, and Sweden. At 2 years, 66% of patients in the 60 Gy group were alive, compared with 39% in the 45 Gy group. The higher radiotherapy dose of 60 Gy resulted in a substantial survival improvement.
